Co-formulation of P-glycoprotein substrate and inhibitor in nanocarriers: An emerging strategy for cancer chemotherapy

Current Cancer Drug Targets

Volumn 14, Issue 5, 2014, Pages 419-433

  Saneja, Ankit ^a,b   Dubey, Ravindra Dhar ^b   Alam, Noor ^b   Khare, Vaibhav ^b   Gupta, Prem N ^a,b  

^a ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^b CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Anticancer drugs; Co formulation; Multi drug resistance; Nanocarriers; P glycoprotein inhibitor

Indexed keywords

ABC TRANSPORTER; CHITOSAN; CURCUMIN; CYTOCHROME P450; DENDRIMER; DOFEQUIDAR; DOXORUBICIN; ELACRIDAR; ERYTHROMYCIN; GLYCOPROTEIN P INHIBITOR; KETOCONAZOLE; LIDOCAINE; LIPOSOME; LIPUSU; MAGNETIC NANOPARTICLE; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; NANOPARTICLE; QUERCETIN; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; STEARIC ACID; TAMOXIFEN; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE; VINCRISTINE SULFATE; ZOSUQUIDAR; ANTINEOPLASTIC AGENT; DRUG CARRIER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CAENORHABDITIS ELEGANS; CANCER CHEMOTHERAPY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; EFFUSION; ENCAPSULATION; ENDOCYTOSIS; ENZYME INHIBITION; HUMAN; LIVER CELL CARCINOMA; MICELLE; MICELLIZATION; MULTIDRUG RESISTANCE; NANOCARRIER DRUG DELIVERY SYSTEM; NANOEMULSION; NONHUMAN; POLYMERIZATION; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; ANTAGONISTS AND INHIBITORS; MEDICINAL CHEMISTRY; METABOLISM; NANOTECHNOLOGY; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; NANOTECHNOLOGY; NEOPLASMS; P-GLYCOPROTEIN;

EID: 84904722192     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140407112034     Document Type: Article

References (81)

1. Bansal, T.; Akhtar, N.; Jaggi, M.; Khar, R. K.; Talegaonkar, S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov. Today 2009, 14(21), 1067-1074.
2. Creixell, M.; Peppas, N. A. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 2012, 7, 367-379.
3. Saneja, A.; Khare, V.; Alam, N.; Dubey, R. D.; Gupta, P. N. Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opin. Drug Deliv. 2014, 11(1), 121-138.
4. Juliano, R. L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 1976, 455(1), 152-162.
5. Montesinos, R. N.; Beduneau, A.; Pellequer, Y.; Lamprecht, A. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J. Control. Release 2012, 161, 50-61.
6. McDevitt, C. A.; Callaghan, R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol. Ther. 2007, 113(2), 429-441.
7. Binkhathlan, Z.; Lavasanifar, A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr. Cancer Drug Targets 2013, 13(3), 326-346.
8. Mazzaferro, S.; Bouchemal, K.; Ponchel, G. Oral delivery of anticancer drugs III: Formulation using drug delivery systems. Drug Discov. Today 2013, 18(1-2), 99-104.
9. Parhi, P.; Mohanty, C.; Sahoo, S. K. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov. Today 2012, 17, 1044-1052.
10. Varma, M. V. S.; Ashokraj, Y.; Dey, C. S.; Panchagnula, R. Pglycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 2003, 48(4), 347-359.
11. Ambudkar, S. V.; Kimchi-Sarfaty, C.; Sauna, Z. E.; Gottesman, M. M. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22(47), 7468-7485.
12. Marzolini, C.; Paus, E.; Buclin, T.; Kim, R. B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 2004, 75(1), 13-33.
13. Ana, F.; Gilberto, A.; Falcao, A. In vitroand in vivorelevance of the p-glycoprotein probe substrates in drug discovery and development: focus on rhodamine 123, digoxin and talinolol. J. Bioequ. Bioavail. 2011, 2, 1-23.
14. Altenberg, G. A.; Vanoye, C. G.; Horton, J. K.; Reuss, L. Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc. Natl. Acad. Sci. USA 1994, 91(11), 4654-4657.
15. Higgins, C. F.; Gottesman, M. M. Is the multidrug transporter a flippase? Trend. Biochem. Sci. 1992, 17(1), 18-21.
16. Raviv, Y.; Pollard, H. B.; Bruggemann, E. P.; Pastan, I.; Gottesman, M. M. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. 1990, 265(7), 3975-3980.
17. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323(5922), 1718-1722.
18. Jin, M. S.; Oldham, M. L.; Zhang, Q.; Chen, J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 2012, 490(7421), 566-569.
19. Ward, A. B.; Szewczyk, P.; Grimard, V.; Lee, C.-W.; Martinez, L.; Doshi, R.; Caya, A.; Villaluz, M.; Pardon, E.; Cregger, C. Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc. Natl. Acad. Sci. USA 2013, 110(33), 13386-13391.
20. Li, J.; Jaimes, K. F.; Aller, S. G. Refined structures of mouse Pglycoprotein. Protein Sci. 2013, 23(1), 34-46.
21. Foger, F. In: Oral Delivery of Macromolecular Drugs; Andreas Bernkop-Schnürch, Ed.; Springer, 2009; pp. 123-136.
22. Bansal, T.; Jaggi, M.; Khar, R.; Talegaonkar, S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci. 2009, 12(1), 46-78.
23. Najar, I. A.; Sharma, S. C.; Singh, G. D.; Koul, S.; Gupta, P. N.; Javed, S.; Johri, R. K. Involvement of P-glycoprotein and CYP 3A4 in the enhancement of etoposide bioavailability by a piperine analogue. Chem. Biol. Int. 2011, 190(2), 84-90.
24. Sachin, B. S.; Najar, I. A.; Sharma, S. C.; Verma, M. K.; Reddy, M. V.; Anand, R.; Khajuria, R. K.; Koul, S.; Johri, R. K. Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC-qTOF-MS: Evidence that PA-1 enhances the oral bioavailability of etoposide in mice. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2010, 878(9), 823-830.
25. Chearwae, W.; Anuchapreeda, S.; Nandigama, K.; Ambudkar, S. V.; Limtrakul, P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem. Pharmacol. 2004, 68(10), 2043-2052.
26. Wu, C. P.; Ohnuma, S.; Ambudkar, S. V. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr. Pharm. Biotechnol. 2011, 12(4), 609-620.
27. Li, Y.; Paxton, J. W. The effects of flavonoids on the ABC transporters: consequences for the pharmacokinetics of substrate drugs. Expert Opin. Drug. Metab. Toxicol. 2013, 9(3), 267-285.
28. Shukla, S.; Wu, C. P.; Ambudkar, S. V. Development of inhibitors of ATP-binding cassette drug transporters-present status and challenges. Expert Opin. Drug. Metab. Toxicol. 2008, 4(2), 205-223.
29. Acharya, S.; Sahoo, S. K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug Deliv. Rev. 2011, 63(3), 170-183.
30. Sosnik, A. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing 'Generally Recognized As Safe' (GRAS) nanopharmaceuticals: A review. Adv. Drug Deliv. Rev. 2013, 65(13), 1828-1851.
31. Collnot, E. M.; Baldes, C.; Schaefer, U. F.; Edgar, K. J.; Wempe, M. F.; Lehr, C. M. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol. Pharm. 2010, 7(3), 642-651.
32. Collnot, E. M.; Baldes, C.; Wempe, M. F.; Kappl, R.; Hattermann, J. R.; Hyatt, J. A.; Edgar, K. J.; Schaefer, U. F.; Lehr, C. M. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol. Pharm. 2007, 4(3), 465-474.
33. Zhu, H.; Chen, H.; Zeng, X.; Wang, Z.; Zhang, X.; Wu, Y.; Gao, Y.; Zhang, J.; Liu, K.; Liu, R. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. Biomaterials 2013, 1-10.
34. Lo, Y. l. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control. Release 2003, 90(1), 37-48.
35. Buggins, T. R.; Dickinson, P. A.; Taylor, G. The effects of pharmaceutical excipients on drug disposition. Adv. Drug Deliv. Rev. 2007, 59(15), 1482-1503.
36. Constantinides, P. P.; Wasan, K. M. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: In vitro/In vivocase studies. J. Pharm. Sci. 2007, 96(2), 235-248.
37. Lu, Y.; Park, K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. 2013, 453, 198-214.
38. Sane, R.; Mittapalli, R. K.; Elmquist, W. F. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J. Pharm. Sci. 2013, 102, 1343-1354.
39. Krishna, R.; McIntosh, N.; Riggs, K. W.; Mayer, L. D. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin. Cancer Res. 1999, 5(10), 2939-2947.
40. Krishna, R.; St-Louis, M.; Mayer, L. D. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int. J. Cancer 2000, 85(1), 131-141.
41. Gao, P.; Rush, B. D.; Pfund, W. P.; Huang, T.; Bauer, J. M.; Morozowich, W.; Kuo, M. S.; Hageman, M. J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 2003, 92(12), 2386-2398.
42. Park, J. H.; Park, J. H.; Hur, H. J.; Woo, J. S.; Lee, H. J. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. Eur. J. Pharm. Sci. 2012, 45(3), 296-301.
43. Song, X. R.; Cai, Z.; Zheng, Y.; He, G.; Cui, F. Y.; Gong, D. Q.; Hou, S. X.; Xiong, S. J.; Lei, X. J.; Wei, Y. Q. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci. 2009, 37(3), 300-305.
44. Xiong, X. B.; Lavasanifar, A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS nano 2011, 5(6), 5202-5213.
45. Mei, L.; Zhang, Z.; Zhao, L.; Huang, L.; Yang, X. L.; Tang, J.; Feng, S. S. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv. Drug Deliv. Reviews 2013, 65, 880-890.
46. Thanki, K.; Gangwal, R.; Sangamwar, A. T.; Jain, S. Oral delivery of anticancer drugs: challenges and opportunities. J. Control. Release 2013, 170(1), 15-40.
47. Werle, M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm. Res. 2008, 25(3), 500-511.
48. Emilienne Soma, C.; Dubernet, C.; Bentolila, D.; Benita, S.; Couvreur, P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000, 21(1), 1-7.
49. Patil, Y.; Sadhukha, T.; Ma, L.; Panyam, J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 2009, 136(1), 21-29.
50. Song, X. R.; Zheng, Y.; He, G.; Yang, L.; Luo, Y. F.; He, Z. Y.; Li, S. Z.; Li, J. M.; Yu, S.; Luo, X. Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma. J. Pharm. Sci. 2010, 99(12), 4874-4879.
51. Misra, R.; Sahoo, S. K. Co-formulation of doxorubicin and curcumin in poly(D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol. Pharm. 2011, 8(3), 852-66.
52. Duan, J.; Mansour, H. M.; Zhang, Y.; Deng, X.; Chen, Y.; Wang, J.; Pan, Y.; Zhao, J. Reversion of multidrug resistance by coencapsulation of doxorubicin and curcumin in chitosan/poly (butyl cyanoacrylate) nanoparticles. Int. J. Pharm. 2012, 426(1), 193-201.
53. Bisht, S.; Mizuma, M.; Feldmann, G.; Ottenhof, N. A.; Hong, S.-M.; Pramanik, D.; Chenna, V.; Karikari, C.; Sharma, R.; Goggins, M. G. Systemic administration of polymeric nanoparticleencapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol. Cancer Ther. 2010, 9(8), 2255-2264.
54. Pramanik, D.; Campbell, N. R.; Das, S.; Gupta, S.; Chenna, V.; Bisht, S.; Sysa-Shah, P.; Bedja, D.; Karikari, C.; Steenbergen, C. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget 2012, 3(6), 640.
55. Jain, A. K.; Thanki, K.; Jain, S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral Bioavailability, antitumor efficacy, and drug-Induced toxicity. Mol. Pharm. 2013, 10(9), 3459-3474.
56. Muller, R. H.; Ruhl, D. R.; Runge, S. A. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int. J. Pharm. 1996, 144(1), 115-121.
57. Wong, H. L.; Bendayan, R.; Rauth, A. M.; Wu, X. Y. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymerlipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control. Release 2006, 116(3), 275-284.
58. Arruebo, M.; Fernandez-Pacheco, R.; Ibarra, M. R.; Santamaria, J. S. Magnetic nanoparticles for drug delivery. Nano Today 2007, 2(3), 22-32.
59. Chen, B.; Sun, Q.; Wang, X.; Gao, F.; Dai, Y.; Yin, Y.; Ding, J.; Gao, C.; Cheng, J.; Li, J. Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4loaded with adriamycin and tetrandrine in K562/A02 leukemic cells. Int. J. Nanomedicine 2008, 3(2), 277-286.
60. Song, X.; Zhao, Y.; Hou, S.; Xu, F.; Zhao, R.; He, J.; Cai, Z.; Li, Y.; Chen, Q. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur. J. Pharm. Biopharm. 2008, 69(2), 445-453.
61. Koudelka, S.; Turanek, J. Liposomal paclitaxel formulations. J. Control. Release 2012, 163, 322-334.
62. Immordino, M. L.; Dosio, F.; Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 2006, 1(3), 297-315.
63. Wang, J.; Goh, B.; Lu, W.; Zhang, Q.; Chang, A.; Liu, X. Y.; Tan, T. M. C.; Lee, H. In vitrocytotoxicity of Stealth liposomes coencapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol. Pharma. Bull. 2005, 28(5), 822-828.
64. Wang, J. C.; Liu, X. Y.; Lu, W.-L.; Change Qiang Zhang, A.; Goh, B. C.; Lee, H. S. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. Eur. J. Pharm. Biopharm. 2006, 62(1), 44-51.
65. Wu, J.; Lu, Y.; Lee, A.; Pan, X.; Yang, X.; Zhao, X.; Lee, R. J. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 2007, 10(3), 350-357.
66. Du, J.; Lu, W.-L.; Ying, X.; Liu, Y.; Du, P.; Tian, W.; Men, Y.; Guo, J.; Zhang, Y.; Li, R. J. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol. Pharm. 2009, 6(3), 905-917.
67. Pang, Z.; Feng, L.; Hua, R.; Chen, J.; Gao, H.; Pan, S.; Jiang, X.; Zhang, P. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol. Pharm. 2010, 7(6), 1995-2005.
68. Discher, D. E.; Eisenberg, A. Polymer vesicles. Science 2002, 297(5583), 967-973.
69. Discher, D. E.; Ahmed, F. Polymersomes. Annu. Rev. Biomed. Eng. 2006, 8, 323-341.
70. Patel, N. R.; Rathi, A.; Mongayt, D.; Torchilin, V. P. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int. J. Pharm. 2011, 416(1), 296-299.
71. Wong, M.-Y.; Chiu, G. N. C. Liposome formulation of coencapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine 2011, 7(6), 834-840.
72. Bajelan, E.; Haeri, A.; Vali, A. M.; Ostad, S. N.; Dadashzadeh, S. Co-delivery of doxorubicin and PSC 833 (valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. J. Pharm. Pharm. Sci. 2012, 15(4), 568-582.
73. Pramanik, D.; Majeti, B. K.; Mondal, G.; Karmali, P. P.; Sistla, R.; Ramprasad, O. G.; Srinivas, G.; Pande, G.; Chaudhuri, A. Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic α5β1 integrin receptor and mouse tumor vasculature. J. Med. Chem. 2008, 51(22), 7298-7302.
74. Barui, S.; Saha, S.; Mondal, G.; Haseena, S.; Chaudhuri, A. Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature. Biomaterials 2014, 35(5), 1643-1656.
75. Wang, F.; Zhang, D.; Zhang, Q.; Chen, Y.; Zheng, D.; Hao, L.; Duan, C.; Jia, L.; Liu, G.; Liu, Y. Synergistic effect of folatemediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance. Biomaterials 2011, 32(35), 9444-9456.
76. Sarisozen, C.; Vural, I.; Levchenko, T.; Hincal, A. A.; Torchilin, V. P. PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells. Drug Deliv. 2012, 19(4), 169-176.
77. Sarisozen, C.; Vural, I.; Levchenko, T.; Hincal, A. A.; Torchilin, V. P. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. Drug Deliv. 2012, 19(8), 363-370.
78. Duan, X.; Xiao, J.; Yin, Q.; Zhang, Z.; Yu, H.; Mao, S.; Li, Y. Smart pH-Sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS nano 2013, 7(7), 5858-5869.
79. Ganta, S.; Amiji, M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 2009, 6(3), 928-939.
80. Jain, A. K.; Thanki, K.; Jain, S. Solidified self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen: part I. formulation development, statistical optimization, and in vitrocharacterization. Pharm. Res. 2013, 1-23.
81. Jain, A. K.; Thanki, K.; Jain, S., Solidified self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen: part II in vivopharmacokinetics, antitumor efficacy and hepatotoxicity. Pharm. Res. 2013, 1-13.